MIM
ESPR

MetLife Investment Management’s Esperion Therapeutics ESPR Stock Holding History

MetLife Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$265K Sell
96,652
-33,083
-26% -$105K ﹤0.01% 2080
2025
Q4 		$480K Buy
129,735
+23,259
+22% +$75.2K ﹤0.01% 1807
2025
Q3 		$282K Sell
106,476
-16,027
-13% -$31K ﹤0.01% 2120
2025
Q2 		$121K Buy
122,503
+47,717
+64% +$47.8K ﹤0.01% 2450
2025
Q1 		$108K Sell
74,786
-42,946
-36% -$79.1K ﹤0.01% 2491
2024
Q4 		$259K Buy
117,732
+46,682
+66% +$109K ﹤0.01% 2164
2024
Q3 		$117K Buy
71,050
+22,734
+47% +$45.9K ﹤0.01% 2565
2024
Q2 		$107K Buy
+48,316
New +$114K ﹤0.01% 2571
2023
Q2 		– Sell
-13,642
Closed -$21.7K – 2954
2023
Q1 		$21.7K Sell
13,642
-21,044
-61% -$109K ﹤0.01% 2771
2022
Q4 		$216K Hold
34,686
– – ﹤0.01% 2202
2022
Q3 		$232K Buy
34,686
+4,925
+17% +$33.8K ﹤0.01% 2197
2022
Q2 		$189K Sell
29,761
-5,349
-15% -$30.3K ﹤0.01% 2362
2022
Q1 		$163K Buy
+35,110
New +$151K ﹤0.01% 2474
2021
Q4 		– Sell
-5,894
Closed -$71K – 2519
2021
Q3 		$71K Sell
5,894
-6,792
-54% -$98.9K ﹤0.01% 2512
2021
Q2 		$268K Hold
12,686
– – ﹤0.01% 1965
2021
Q1 		$356K Hold
12,686
– – ﹤0.01% 1716
2020
Q4 		$330K Hold
12,686
– – ﹤0.01% 1707
2020
Q3 		$472K Hold
12,686
– – 0.01% 1392
2020
Q2 		$651K Buy
12,686
+1,785
+16% +$74.7K 0.01% 1239
2020
Q1 		$344K Hold
10,901
– – ﹤0.01% 1418
2019
Q4 		$650K Hold
10,901
– – 0.01% 1311
2019
Q3 		$400K Hold
10,901
– – ﹤0.01% 1546
2019
Q2 		$507K Hold
10,901
– – 0.01% 1472
2019
Q1 		$438K Hold
10,901
– – ﹤0.01% 1537
2018
Q4 		$501K Hold
10,901
– – 0.01% 1369
2018
Q3 		$484K Hold
10,901
– – 0.01% 1571
2018
Q2 		$427K Buy
10,901
+3,363
+45% +$170K 0.01% 1499
2018
Q1 		$545K Hold
7,538
– – 0.01% 1323
2017
Q4 		$496K Buy
+7,538
New +$406K 0.01% 1392

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's ESPR Position: Q1 2026 in Review

MetLife Investment Management reduced its Esperion Therapeutics (ESPR) stake by 26% in Q1 2026, selling an estimated $105K and leaving 96,652 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

MetLife Investment Management first reported a position in ESPR in Q4 2017 and has held it in 29 quarters since. The position peaked at $651K in Q2 2020. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • MetLife Investment Management held 96,652 shares of Esperion Therapeutics worth $265K as of Q1 2026.
  • MetLife Investment Management sold 33,083 Esperion Therapeutics shares in Q1 2026, an estimated $105K.
  • Esperion Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2080 holding.
  • MetLife Investment Management first reported a position in Esperion Therapeutics in Q4 2017 and has held it in 29 quarters since.
  • MetLife Investment Management's Esperion Therapeutics position peaked at $651K in Q2 2020.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.